Morgan Stanley Innate Pharma Sa Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IPHA
# of Institutions
9Shares Held
238KCall Options Held
0Put Options Held
0-
Optiver Holding B.V. Amsterdam, P786.8KShares$147,5390.01% of portfolio
-
Exchange Traded Concepts, LLC77.4KShares$131,4950.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il21.3KShares$36,1530.0% of portfolio
-
Ubs Group Ag8.41KShares$14,2930.0% of portfolio
-
Barclays PLC London, X0307Shares$5210.0% of portfolio
About Innate Pharma SA
- Ticker IPHA
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 79,893,000
- Market Cap $136M
- Description
- Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphera...